Axsome Doses First Patient in SUMMIT Trial
Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The initiation of the SUMMIT Phase 3 trial represents a positive development for Axsome Therapeutics, potentially expanding the commercial indications of AXS-05 into the large smoking cessation market. Successful trial results could significantly boost Axsome's revenue prospects, while failure could negatively impact its stock.
Axsome Therapeutics announced on August 31, 2026, that the first patient has been dosed in the SUMMIT Phase 3 clinical trial of AXS-05 for smoking cessation. SUMMIT is a randomized, double-blind, active- and placebo-controlled, multicenter trial that will evaluate the efficacy and safety of AXS-05 in adult smokers. Approximately 34 million adults in the U.S. smoke cigarettes, and smoking is the leading cause of preventable disease, costing over $300 billion annually. AXS-05 is an investigational oral NMDA receptor antagonist, sigma-1 agonist, and CYP2D6 inhibitor, already approved as AUVELITY for major depressive disorder and agitation associated with Alzheimer's disease. The trial will randomize smokers to receive AXS-05, bupropion, or placebo for about 12 weeks, with the primary endpoint being smoking abstinence at the end of treatment. This milestone advances Axsome's pipeline in a high unmet need area.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard